Curosurf
Curosurf Uses, Dosage, Side Effects, Food Interaction and all others data.
Curosurf is a pulmonary surfactant marketed as Curosurf in the United States and Canada. It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. Curosurf is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). The phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. Curosurf is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives.
Curosurf improved lung compliance, pulmonary gas exchange and survival in preterm rabbits.
| Trade Name | Curosurf |
| Generic | Poractant alfa |
| Type | Injection, Suspension, Intratracheal Suspension |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | Chiesi Pharmaceuticals (pvt) Ltd, , Chiesi Limited, Abbott Healthcare Pvt Ltd, Chiesi Farmaceutici |
| Available Country | Pakistan, United Kingdom, India, United States, Netherlands, Portugal, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Curosurf is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Curosurf is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Curosurf is also used to associated treatment for these conditions: Respiratory Distress Syndrome
How Curosurf works
Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli in the lungs, thus stabilizing them against collapse under transpulmonary pressures. A deficiency of pulmonary surfactant in premature infants allows surface tension to increase to the point where sections of lung collapse and respiratory distress syndrome (RDS) develops. Curosurf lowers minimum surface tension to less than or equal to 4 mN/m. This compensates for the lack of endogenous surfactant and restores adequate surface activity to the lungs.
Toxicity
Studies on the carcinogenicity or reproductive effects of poractant alfa have not been conducted. Mutagenicity assays were negative. In the case of an overdose with poractant alfa where there are clear clinical effects on the infant's respiration, ventilation, or oxygenation, it is recommended that as much of the solution be aspirated as possible and the infant be managed with supportive measures. Fluid and electrolyte balances should be monitored closely in this case.
Food Interaction
No interactions found.Volume of Distribution
No studies on the distribution of poractant alfa have been performed in humans.
Elimination Route
Curosurf is administered directly to the site of action in the lungs via endotracheal tube. It very rapidly adsorbs to the air-liquid interface to form a stable surfactant monolayer. No studies on absorption of poractant alfa have been performed in humans.
Half Life
The half-life of poractant alfa has only been evaluated in animal studies. When studied in adult and newborn rabbits, the half-life in the lungs was found to be 25 and 67 respectively.
Clearance
No studies on clearance of poractant alfa have been performed in humans.
Elimination Route
No studies on elimination of poractant alfa have been performed in humans.
Innovators Monograph
You find simplified version here Curosurf
